ArticleFrontiers in medicine2026
Pharmacokinetics of intravenous oxycodone hydrochloride in perioperative patients with liver cancer.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Effective perioperative analgesia in liver cancer patients presents an ongoing clinical challenge. This study investigates oxycodone's pharmacokinetics in perioperative liver cancer patients with normal liver function to support individualized analgesia. Methods: This study developed and validated a reliable high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method for the simultaneous quantification of oxycodone and its metabolite noroxycodone in human plasma. The method was successfully applied to characterize the pharmacokinetics in nine surgical liver cancer patients following intravenous oxycodone administration, using non-compartmental analysis (NCA). Results: The developed method showed satisfactory linearity and met validation criteria. In perioperative liver cancer patients, oxycodone exhibited reduced clearance, prolonged half-life, increased volume of distribution, and elevated exposure compared with healthy volunteers. Its metabolite noroxycodone displayed a biphasic profile with consistently higher concentrations in males. Significant sex-related differences were also observed for oxycodone's area under the plasma concentration-time curve (AUC) and mean residence time (MRT). Discussion: This study reveals that compared with healthy volunteers, perioperative liver cancer patients with normal liver function exhibit significantly altered oxycodone pharmacokinetics, including reduced clearance, prolonged half-life, increased exposure and volume of distribution, with notable sex differences. These findings support the need for dose reduction, extended monitoring, and individualized analgesic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.